M&A Deal Summary

Proteintech Group Acquires ChromoTek

On October 20, 2020, Proteintech Group acquired life science company ChromoTek

Acquisition Highlights
  • This is Proteintech Group’s 2nd transaction in the Life Science sector.
  • This is Proteintech Group’s 1st transaction in Germany.

M&A Deal Summary

Date 2020-10-20
Target ChromoTek
Sector Life Science
Buyer(s) Proteintech Group
Deal Type Add-on Acquisition

Target

ChromoTek

Planegg-Martinsried, Germany
ChromoTek GmbH is a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. ChromoTek offers nanobodies high-performance recombinant reagents used for breakthrough research discoveries. ChromoTek was established in 2008 and is based in Planegg-Martinsried, Germany.

Search 215,130 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Proteintech Group

Rosemont, Illinois, United States

Category Company
Sector Life Science
DESCRIPTION

Proteintech Group, Inc. is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. Proteintech Group is based in Rosemont, Illinois.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Germany M&A 1 of 1
Year: 2020 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-04-16 HumanZyme

Chicago, Illinois, United States

HumanZyme, Inc. is a manufacturer of human cell-expressed proteins. It has developed the HumaXpress human cell expression system, which produces authentic recombinant HumanKine™ proteins with correct post-translational modifications, subunit assembly, folding, secretion, and stability to ensure the best possible results.

Buy -